EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy

Ian Messing iD, Lauren Linkowski, Matthew D Riina, Melanie Berger, Jonathan Baron, Xingmei Wang, Michael Kallan, Harper G Hubbeling, Robert A Lustig, Jay F Dorsey, Goldie Kurtz, Suneel Nagda und 12 weitere

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Ian Messing und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, United States. Hauptthemen laut MEDLINE: Melanoma, Brain Neoplasms, Ipilimumab, Nivolumab. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Melanoma brain metastases (BM) carry high morbidity and mortality despite advances in systemic therapy. Combined immune checkpoint inhibition (ICI) with ipilimumab and nivolumab (ipi/nivo) demonstrates intracranial activity, but the influence of prior systemic therapy exposure is poorly defined. This is the first real-world study evaluating outcomes of melanoma BM treated with stereotactic radiosurgery (SRS) and concurrent ipi/nivo, focusing on the impact of prior ICI or targeted therapy. Patients and Methods We retrospectively analyzed 68 patients with 413 melanoma BM treated with concurrent SRS and ipi/nivo from 2015–2025. Primary endpoints were overall survival (OS) and intracranial progression-free survival (iPFS). Secondary endpoints included local and distant control, radionecrosis, and leptomeningeal disease. Univariable and multivariable Cox models identified predictors of outcome.

Results

Median OS was 24.0 months (12- and 24-month OS: 64% and 50%). ICI-naive patients had longer OS (50.5 vs 17.6 months; P = .007) and iPFS (15.1 vs 5.9 months) than those with prior ICI. On multivariable analysis, prior ICI (HR 2.23, 95% CI 1.13–4.41), prior BRAF/MEKi (HR 2.26, 95% CI 1.01–5.04), and ≥11 SRS-treated lesions (HR 3.22, 95% CI 1.43–7.21) predicted worse outcomes, while higher Graded Prognostic Assessment (GPA) favored OS (HR 0.46, 95% CI 0.29–0.75). At 24 months, local progression was 11%, distant 49%, radionecrosis 7%, and leptomeningeal disease 4%.

Conclusion

Concurrent SRS with ipi/nivo provides durable intracranial control with low toxicity. Patients with prior ICI or targeted therapy represent a high-risk subgroup with poorer outcomes, supporting exploration of intensified or novel strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaBrain NeoplasmsIpilimumabNivolumabRadiosurgeryImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleAgedMiddle AgedRetrospective StudiesAdultAged, 80 and over

Stichwörter der Autor:innen

dual immune checkpoint inhibitionintracranial disease controlipilimumab and nivolumabmelanoma brain metastasesprior immune checkpoint inhibitor exposurestereotactic radiosurgery

Substanzen

IpilimumabNivolumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA 19104, United States.
  • Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, United States.
  • Department of Neurosurgery, University of Pennsylvania, Philadelphia, PA 19104, United States.
  • Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104, United States.

ORCID-Profile: Ian Messing, Suyash Mohan, Emily S Lebow

Förderung

  • NCI NIH HHS

Zitieren

APA

Messing, I., Linkowski, L., Riina, M. D., Berger, M., Baron, J., Wang, X., Kallan, M., Hubbeling, H. G., Lustig, R. A., Dorsey, J. F., Kurtz, G., Nagda, S., Lukens, J. N., Flowers, A., Lee, J. Y. K., Amankulor, N. M., Jackson, C., Mohan, S., Amaravadi, R. K., …, & Lebow, E. S. (2026). Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy. The Oncologist. https://doi.org/10.1093/oncolo/oyag043

Vancouver

Messing I, Linkowski L, Riina MD, Berger M, Baron J, Wang X, et al. Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy. The Oncologist. 2026. doi:10.1093/oncolo/oyag043

BibTeX
@article{Messing2026,
  author = {Messing, Ian and Linkowski, Lauren and Riina, Matthew D and Berger, Melanie and Baron, Jonathan and Wang, Xingmei and Kallan, Michael and Hubbeling, Harper G and Lustig, Robert A and Dorsey, Jay F and Kurtz, Goldie and Nagda, Suneel and Lukens, John N and Flowers, Ahron and Lee, John Y K and Amankulor, Nduka M and Jackson, Christina and Mohan, Suyash and Amaravadi, Ravi K and Schuchter, Lynn M and Huang, Alexander C and Mitchell, Tara C and Alonso-Basanta, Michelle and Lebow, Emily S},
  title = {Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted Therapy},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag043}
}
Kostenlos starten →